Online Program

Return to main conference page
Thursday, September 13
Thu, Sep 13, 4:15 PM - 5:30 PM
Thurgood Marshall South
Developing a PRO for Use as a Phase III Endpoint for Regulatory Approval and Marketing: Implementation of the 2009 FDA Final Guidance for Industry

Estimating Number of Patient Interviews for PRO Development as a Clinical Trial Endpoint Based on the 2009 FDA PRO Guidance (300689)

*Chris Barker, Chris Barker Statistical Planning and Analysis Services 

Keywords: patient reported outcome, PRO, validation, saturation, FDA PRO guidance, capture recapture

PRO's developed de novo, using the 2009 FDA guidance may involve structured patient interviews or focus groups. Qualitative Research is a methodology for coding interviews and produces concepts or themes. These concepts are used to develop items in a PRO. A convention in the field is that interviews and code/concept elicitation are considered complete when subsequent interviews produces "no new concepts" -termed "saturation". The convention in the field is that there are sufficient patient interviews when the first occurrence of an interview with zero new concepts. Several authors have reported that this definition is inadequate and that concrete criteria are needed for confirming that saturation is achieved (Francis 2010, Mason 2010, Marshall 2013). Statistical methods are introduced for prospectively estimating sample size (number of interviews), defining saturation on a probability scale, and Type I error in the saturation process. Capture-recapture methodology is suggested for estimating the number of concepts as early as the second or third interview. On-going Research implements a Bayesian method suitable for small sample sizes.